Tempest Therapeutics

TPST · NASDAQ

$0.5762−$0.0239 (−3.98%)TodayMarket closed ·
Prev close $0.6001

Latest news

  • Press releaseGlobe Newswire

    Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

  • Press releaseGlobe Newswire

    Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • NewsHenry Khederian

    Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?

  • Press releaseGlobe Newswire

    Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

  • Press releaseGlobe Newswire

    Tempest Therapeutics Announces Up to $7.5 Million Private Placement

  • Press releaseGlobe Newswire

    Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releaseGlobe Newswire

    Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

  • Press releaseGlobe Newswire

    Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

  • Press releaseGlobe Newswire

    Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

  • Press releaseGlobe Newswire

    Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

  • Press releaseGlobe Newswire

    Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

  • News

    12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releaseGlobe Newswire

    Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseGlobe Newswire

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • NewsAvi Kapoor

    Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • NewsAvi Kapoor

    Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast

  • NewsHenry Khederian

    Why Tempest Therapeutics (TPST) Stock Is Down 45% Today

  • News

    12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releasePRNewswire

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • NewsAvi Kapoor

    Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

  • NewsVandana Singh

    Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.